XS-04

Primary objective: Evaluate the safety and tolerability of XS-04 tablets in patients with relapsed or refractory hematological malignancies. Determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of XS-04 tablets. Secondary objective: Determine the pharmacokinetic (PK) characteristics of XS-04 tablets after single and multiple oral administration. Preliminary evaluation of the efficacy of XS-04 tablets in patients with relapsed or refractory hematological malignancies. Exploratory objective: Preliminary evaluation of the metabolic conversion characteristics of patients after oral administration of XS-04 tablets. Evaluate population PK and exposure-effect (E-R) relationships. Explore the association between relevant biomarkers and drug efficacy; explore the correlation between PD biomarkers and PK. Evaluate the effect of food on the PK characteristics of patients taking oral XS-04 tablets.